The vision to change the world
Life–changing therapy by global leaders in ophthalmology
Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. We are led by a team of world-renowned ophthalmology academics, researchers and a board with a proven track record in MedTech innovation, implementation, and clinical facilitation.
Patented childhood myopia control therapy
Eyerising International’s Myopia Management Repeated Low-Level Red–Light (RLRL) therapy was conceived and developed by ERI’s Chief Medical Officer, Professor Mingguang He, a global leader in myopia control and the development of artificial intelligence systems in ophthalmology. This innovation in childhood myopia control meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia.
View our most important scientific papers
A 12-month clinical trial conducted on 264 participants published on Ophthalmology
24-month follow-up clinical trial conducted on 199 participants published on CEO
Clinical trial to assess the efficacy and safety of treatment in controlling myopia progression compared to a sham device with only 10% of the original power published on Ophthalmology
A multicenter, randomized controlled trial (RCT) to evaluate longitudinal changes in macular choroidal thickness in myopic children treated for one year with the treatment published on Ophthalmology
Clinically Significant Axial Shortening in Myopic after RLRL
Axial Shortening in Myopic Children after Repeated Low-Level Red-Light Therapy
News and press releases
A Game-Changer in Myopia Management is Now Available in Malaysia
We are excited to announce that our new partner in Malaysia, Transmedic Ophthalmology, will be launching and showcasing the Eyerising Myopia Management Device at the World Congress of Paediatric Ophthalmology and Strabismus (WCPOS) in Kuala[...]
Study Finds Red Light Therapy Cuts Ocular Elongation Rate and SER Increase
Article outlines the amazing results of RLRL in high myopia patients. “Repeated low-level red light demonstrates much stronger treatment efficacy among high myopia in children and adolescents aged six to 16 years, with 53.3% experiencing[...]
Mark your calendars for July 12!
Join us at the World Congress of Paediatric Ophthalmology and Strabismus, breakfast symposium for an insightful panel discussion on Repeated Low-Level Red-Light Therapy for Myopia, featuring a panel of world-class experts. Don't miss this opportunity[...]
3rd Ho Chi Minh City Ophthalmology Conference 2024
With an aim to provide a solution to the increasing number of children with myopia, we are proud to introduce Repeated Low-Level Red-Light Therapy (RLRL) in Vietnam. We will be attending the 3rd Ho Chi[...]
The UK Perspective on Eyerising’s RLRL Myopia Management Device
The buzz around repeated low-level red light therapy (RLRL) is growing, stemming from multiple studies coming out of China. But is it just as effective in the UK? At recent global optometry conference, Dr. Neema[...]
Repeated Low-Level Red Light Therapy for Myopia Control in High Myopia Children and Adolescents: A Randomized Clinical Trial
Exciting news! A new Randomized Clinical Trial on Repeated Low-Level Red-Light Therapy (RLRL) for Myopia Control in High Myopia Children has just been published. This comes just in time for the upcoming RLRL Webinar with[...]
Professor Mingguang He
Founder, Chief Medical Officer
Prof. He has over 25 years of experience in ophthalmology. He is currently a Professor of Ophthalmic Epidemiology at the University of Melbourne and leads ophthalmic epidemiology research at the Centre for Eye Research Australia. His research has led to original articles and invited editorials in respected medical journals, including the Journal of the American Medical Association, Diabetes Care, & Ophthalmology.
Jason Sun
Founder, MD
With a clinical background and over 20+ years of executive experience in the Australian health sector, including 10 years of industry development experience, Mr. Sun brings expertise in Medtech commercialisation, international business, regulatory compliance, and government relations.
Michael Woods
Executive Director
Mr. Woods has been an investor, adviser, board member, and CEO for various life science start-ups and scale-up companies in the life sciences sector.
Manny Pascual
Head of Commercial
Over 20 years of experience in the medical device industry Previous Marketing Director for CooperVision Asia Pacific Previous success in medical device company business expansion and acceleration.
David Holland
Business Development Manager (Australasia)
Federico Roma
CTO Accomplished technology leader
Dr. Yuri Aung
Clinical Affairs and RAQA Manager
Dr. Lisa Zhuoting Zhu
Director of Clinical Development
For any investor questions, please send your queries to:
Email: info@eyerisinginternational.com
Eyerising International Pty Ltd
Head office
Suite 2.05
9/11 Claremont St
South Yarra VIC 3141
